Tag: KDC-MN-1608

  • TUDCA

    Hydrophilic taurine-conjugated bile acid with chemical chaperone activity and endoplasmic reticulum stress modulation

    A taurine conjugate of ursodeoxycholic acid distinguished by chemical chaperone activity at the endoplasmic reticulum, cytoprotective modulation of the unfolded protein response, and broad preclinical neuroprotective and metabolic activity across neurodegenerative, hepatobiliary, retinal, and metabolic disease models.

    Abstract

    Tauroursodeoxycholic acid (TUDCA) is a naturally occurring hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA), identified in bear bile in 1902 and used in traditional Chinese medicine for centuries prior to its modern pharmacological characterization. The compound functions principally as a chemical chaperone that alleviates endoplasmic reticulum (ER) stress by stabilizing the unfolded protein response (UPR) through modulation of the three canonical ER stress sensor pathways: PERK/eIF2alpha/ATF4, IRE1alpha/XBP1, and ATF6. Beyond ER stress modulation, TUDCA exerts potent anti-apoptotic activity through prevention of Bax translocation to mitochondrial membranes, inhibition of cytochrome c release, and activation of the PI3K/Akt survival pathway. The compound stabilizes mitochondrial membrane potential, reduces reactive oxygen species production, suppresses NF-kappaB-mediated proinflammatory cytokine release, and activates the nuclear receptor FXR and the membrane receptor TGR5. TUDCA crosses the blood-brain barrier and has demonstrated neuroprotective activity in preclinical models of Alzheimer’s disease (APP/PS1 transgenic mice, reducing amyloid-beta deposition and rescuing spatial memory), Parkinson’s disease (MPTP model, preventing dopaminergic neuronal loss), Huntington’s disease (3-nitropropionic acid model, preserving striatal mitochondria), amyotrophic lateral sclerosis (SOD1 transgenic mice), retinal degeneration (multiple retinitis pigmentosa models), and ischemic stroke (reducing infarct volume by approximately 50 percent). A separate European Phase III trial (TUDCA-ALS) of TUDCA monotherapy in 337 ALS patients similarly failed to demonstrate efficacy at 18 months. The compound has been licensed for the treatment of cholestatic liver disease and cholesterol gallstones in several European and Asian jurisdictions since 1991 and maintains a favorable safety profile, with the principal adverse events being mild gastrointestinal effects (diarrhea in approximately 14 percent, abdominal pain in approximately 6 percent). This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.